[go: up one dir, main page]

AR002254A1 - Formulacion antitrombotica y procedimiento para su manufactura - Google Patents

Formulacion antitrombotica y procedimiento para su manufactura

Info

Publication number
AR002254A1
AR002254A1 ARP950100405A AR10040595A AR002254A1 AR 002254 A1 AR002254 A1 AR 002254A1 AR P950100405 A ARP950100405 A AR P950100405A AR 10040595 A AR10040595 A AR 10040595A AR 002254 A1 AR002254 A1 AR 002254A1
Authority
AR
Argentina
Prior art keywords
formulation
procedure
manufacture
antithrombotic
pharmaceutical formulation
Prior art date
Application number
ARP950100405A
Other languages
English (en)
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of AR002254A1 publication Critical patent/AR002254A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una nueva formulación farmacéutica que comprende el inhibidor de trombina HOOC-CH2-(R)-Cgl-Aze-Pab en combinación con uno o más agentes mejoradores deabsorción y un procedimiento para la preparación de dicha formulación farmacéutica. Dicha formulación es útil para el tratamiento de tromboembolismoen un paciente que necesita tratamiento antitrombótico.
ARP950100405A 1994-12-02 1995-11-30 Formulacion antitrombotica y procedimiento para su manufactura AR002254A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9404196A SE9404196D0 (sv) 1994-12-02 1994-12-02 New antithrombotic formulation

Publications (1)

Publication Number Publication Date
AR002254A1 true AR002254A1 (es) 1998-03-11

Family

ID=20396207

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP950100405A AR002254A1 (es) 1994-12-02 1995-11-30 Formulacion antitrombotica y procedimiento para su manufactura

Country Status (27)

Country Link
US (1) US5795896A (es)
EP (1) EP0799052B1 (es)
JP (1) JPH10513438A (es)
CN (1) CN1168635A (es)
AR (1) AR002254A1 (es)
AT (1) ATE208628T1 (es)
AU (1) AU689994B2 (es)
BR (1) BR9509853A (es)
CA (1) CA2206459A1 (es)
CZ (1) CZ147097A3 (es)
DE (1) DE69523943T2 (es)
DK (1) DK0799052T3 (es)
EE (1) EE03338B1 (es)
ES (1) ES2168395T3 (es)
FI (1) FI972332A7 (es)
HU (1) HU216631B (es)
IL (1) IL116153A (es)
IS (1) IS4483A (es)
NO (1) NO972475D0 (es)
NZ (1) NZ297118A (es)
PL (1) PL320692A1 (es)
PT (1) PT799052E (es)
SE (1) SE9404196D0 (es)
SK (1) SK61797A3 (es)
TR (1) TR199501517A2 (es)
WO (1) WO1996016671A1 (es)
ZA (1) ZA9510242B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US6984627B1 (en) * 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
GB9526273D0 (en) * 1995-12-21 1996-02-21 Astra Ab New prodrugs
AR005245A1 (es) * 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
SE9602145D0 (sv) * 1996-05-31 1996-05-31 Astra Ab New improved formulation for treatment of thromboembolism
US6423334B1 (en) * 1997-10-01 2002-07-23 Elan Corporation, Plc Composition and method for enhancing transport across gastrointestinal tract cell layers
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
AR023819A1 (es) * 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
SE9902550D0 (sv) * 1999-07-02 1999-07-02 Astra Ab New crystalline forms
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US6884768B2 (en) * 2001-06-14 2005-04-26 Otsuka Pharmaceutical Co., Ltd. Medicinal compositions
SE0103590D0 (sv) * 2001-10-26 2001-10-26 Astrazeneca Ab New Combination
SE0203349D0 (sv) * 2002-11-12 2002-11-12 Astrazeneca Ab New use
HUE025683T2 (hu) 2002-12-03 2016-04-28 Pharmacyclics Llc VIIA faktor inhibitor 2-(2-hidroxi-bifenil-3-il)-1H-benzoimidazol-5-karboxamidin-származékok
US7345093B2 (en) * 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US20060046962A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
RU2354647C2 (ru) 2007-06-28 2009-05-10 Общество С Ограниченной Ответственностью "Бионика" Новые соединения, обладающие функцией ингибиторов тромбина, и фармацевтические композиции на их основе
CA2756690C (en) 2008-03-28 2016-08-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
US8440631B2 (en) * 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
US20100215730A1 (en) * 2009-02-20 2010-08-26 Intrepid Therapeutics, Inc. Compositions for Nasal Administration of Phenothiazines
US20110070293A1 (en) * 2009-09-23 2011-03-24 Javeri Indu Methods for the Preparation of Liposomes Comprising Docetaxel
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
US20110070294A1 (en) * 2009-09-23 2011-03-24 Javeri Indu Methods for the Administration of Drugs Using Liposomes
DK3415139T3 (da) 2011-06-14 2022-06-20 Neurelis Inc Administration af benzodiazepin
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) * 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
US4568636A (en) * 1981-03-25 1986-02-04 Pentapharm Ag Tripeptide derivatives
US4395401A (en) * 1981-09-09 1983-07-26 Smithkline Beckman Corporation Renally active dipeptides
HU192646B (en) * 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
IL77748A (en) * 1985-02-04 1991-11-21 Merrell Dow Pharma Amino acid and peptide derivatives as peptidase inhibitors
DE3505555A1 (de) * 1985-02-18 1986-09-11 Behringwerke Ag, 3550 Marburg Neue oligopeptidylargininolderivate und deren homologe, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel
PT84170B (pt) * 1986-01-24 1989-03-30 Sanofi Sa Processo para a preparacao de derivados n alfa-substituidos das n alfa-aril-sulfonilaminoacil d-amidinofenil-alaninamidas
DE3606480A1 (de) * 1986-02-28 1987-09-03 Behringwerke Ag Oligopeptidylnitrilderivate, diese enthaltende mittel, verfahren zu ihrer herstellung und ihre verwendung
US5187157A (en) * 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0362002B1 (en) * 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. HIV protease inhibitors
ZA897514B (en) * 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
US5053392A (en) * 1989-12-01 1991-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Novel arginine, glycine, aspartic acid derivatives as platelet-aggregation inhibitors
US5037819A (en) * 1990-06-04 1991-08-06 Bristol-Myers Squibb Company Azetidin-2-one derivatives as serine protease inhibitors
US5110812A (en) * 1990-06-04 1992-05-05 Bristol-Myers Squibb Co. Azetidin-2-one derivatives as serine protease inhibitors
TW201303B (es) * 1990-07-05 1993-03-01 Hoffmann La Roche
GB9017694D0 (en) * 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
GB9019558D0 (en) * 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
IL99527A (en) * 1990-09-28 1997-08-14 Lilly Co Eli Tripeptide antithrombotic agents
GB9024129D0 (en) * 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
JPH05503300A (ja) * 1990-11-15 1993-06-03 ペンタファルム　アクチェンゲゼルシャフト メタ置換フェニルアラニン誘導体
DE4115468A1 (de) * 1991-05-11 1992-11-12 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
SE9102462D0 (sv) * 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
ZA928581B (en) * 1991-11-12 1994-05-06 Lilly Co Eli Antithrombotic agents
SE9103612D0 (sv) * 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives

Also Published As

Publication number Publication date
PT799052E (pt) 2002-05-31
AU4191596A (en) 1996-06-19
FI972332A0 (fi) 1997-06-02
SK61797A3 (en) 1998-03-04
BR9509853A (pt) 1997-12-30
EE03338B1 (et) 2001-02-15
AU689994B2 (en) 1998-04-09
HUT77655A (hu) 1998-07-28
PL320692A1 (en) 1997-10-27
ATE208628T1 (de) 2001-11-15
MX9703975A (es) 1997-09-30
DE69523943T2 (de) 2002-06-27
JPH10513438A (ja) 1998-12-22
ES2168395T3 (es) 2002-06-16
US5795896A (en) 1998-08-18
EP0799052B1 (en) 2001-11-14
NO972475L (no) 1997-05-30
IL116153A0 (en) 1996-01-31
FI972332L (fi) 1997-06-02
HU216631B (hu) 1999-07-28
TR199501517A2 (tr) 1996-07-21
ZA9510242B (en) 1996-06-03
NO972475D0 (no) 1997-05-30
CZ147097A3 (cs) 1998-02-18
EP0799052A1 (en) 1997-10-08
FI972332A7 (fi) 1997-06-02
CN1168635A (zh) 1997-12-24
CA2206459A1 (en) 1996-06-06
NZ297118A (en) 1998-12-23
DE69523943D1 (de) 2001-12-20
IS4483A (is) 1997-05-16
DK0799052T3 (da) 2002-02-25
SE9404196D0 (sv) 1994-12-02
WO1996016671A1 (en) 1996-06-06
IL116153A (en) 1999-11-30

Similar Documents

Publication Publication Date Title
AR002254A1 (es) Formulacion antitrombotica y procedimiento para su manufactura
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
SE8803486L (sv) Dosform foer behandling av kardiovaskulaera sjukdomar
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
ES2163504T3 (es) Formas de dosificacion de liberacion controlada de azitromicina.
DK463989D0 (da) Farmaceutisk virksom kombination
ATE333896T1 (de) Vaskularisierungsinhibitoren
DE69327263D1 (de) Verwendung des Gewebefaktor-Inhibitors zur Herstellung eines Arzneimittels gegen Mikrogefässthrombose
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
IE900098L (en) The use of the active substance azelastine in combatting¹psoriasis disorders and inflammatory disorders
ES2135703T3 (es) Composicion y procedimiento destinados para prevenir y tratar las inflamaciones con la ayuda de inmunoglobulina.
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
MX169931B (es) Procedimiento para determinar la catividad de serinproteasas inhibidores de serinproteasas
NO960775L (no) Anvendelse av kinoksaliner i kombinasjon med proteaseinhibitorer som legemiddel for behandling av AIDS og/eller HIV-infeksjoner
ES2095578T3 (es) Composicion para el tratamiento de mastitis y metritis.
MX9805506A (es) Uso medico novedoso de un inhibidor de la dispepsia relacionada con acido para el tratamiento de sintomas dispepticos.
NO921223D0 (no) Kombinasjonspreparat med antitrombotisk virkning
ES2072975T3 (es) Mezcla de esterilizante y metodo de esterilizacion.
ES2191206T3 (es) Nueva utilizacion de la creatina.
ES2188611T3 (es) Empleo de granisetron para el tratamiento de las nauseas y vomitos postoperatorios.
ES2085199A1 (es) Un procedimiento para la preparacion de una formulacion depot.
AR004330A1 (es) Uso de inhibidores de colinesterasa en el tratamiento de xerostomia
ES2067221T3 (es) Activador de plasminogeno del tejido que tiene propiedades especificas para la fibrina.
SE8900564D0 (sv) Novel medicinal use
AR013569A1 (es) Nueva formulacion mejorada para el tratamiento de la tromboembolia

Legal Events

Date Code Title Description
FA Abandonment or withdrawal